Concepedia

Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability

Angela Huttner, Sélidji Todagbé Agnandji, Olivier Engler, Jay W. Hooper, Steve Kwilas, Keersten M. Ricks, Tamara L. Clements, Hulda R. Jónsdóttir, Sravya Sowdamini Nakka, Sylvia Rothenberger,

Clinical Microbiology and Infection · 2023 · 22 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

Ana María Henao-Restrepo, Anton Camacho, Ira M. Longini et al. · The Lancet · 2016 · 1.1K citations · Full text

, , +17

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Sélidji Todagbé Agnandji, Angela Huttner, Madeleine E. Zinser et al. · New England Journal of Medicine · 2015 · 413 citations · Full text

, , +17

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

Jason A. Regules, John H. Beigel, Kristopher Paolino et al. · New England Journal of Medicine · 2015 · 395 citations · Full text

, , +11

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

Angela Huttner, Julie-Anne Dayer, Sabine Yerly et al. · The Lancet Infectious Diseases · 2015 · 278 citations

, , +16

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

Placide Mbala‐Kingebeni, Catherine Pratt, Mbusa Mutafali-Ruffin et al. · New England Journal of Medicine · 2021 · 105 citations · Full text

, , +15